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Abstract 
Background: Accumulation of advanced glycation end products (AGEs) leads to chronic glycation of proteins and 
tissue damage, particularly in patients with diabetes mellitus (DM). We aimed to evaluate whether increased accu-
mulation of AGEs in patients with aortic stenosis (AS) and concomitant type 2 diabetes (DM) is associated with AS 
severity.
Methods: We prospectively enrolled 76 patients with severe AS (47.1% males; nonDM), aged 68 [66–72] years, and 50 
age-matched DM patients with a median blood glucose level of 7.5 [5.9–9.1] mM and glycated hemoglobin (HbA1c) 
of 6.8 [6.3–7.8]%, scheduled for aortic valve replacement. Valvular expression of AGEs, AGEs receptor (RAGE), interleu-
kin-6 (IL-6), and reactive oxygen species (ROS) induction were evaluated ex vivo by immunostaining and calculated as 
the extent of positive immunoreactive areas/total sample area. Plasma levels of AGEs and soluble RAGE (sRAGE) were 
assessed by ELISAs.
Results: Subjects with DM had increased valvular expression of both AGEs (6.6-fold higher, 15.53 [9.96–23.28]%) and 
RAGE (1.8-fold higher, 6.8 [4.9–8.45]%) compared to nonDM patients (2.05 [1.21–2.58]% and 2.4 [1.56–3.02]%, respec-
tively; both p < 0.001). Plasma levels of AGEs (12-fold higher) and sRAGE (1.3-fold higher) were elevated in DM patients, 
compared to nonDM (both p < 0.0001). The percentage of valvular ROS-positive (2.28 [1.6–3.09] vs. 1.15 [0.94–1.4]%, 
p < 0.0001) but not IL-6-positive areas was higher within DM, compared to nonDM valves. In DM patients, the percent-
age of valvular AGEs- and RAGE-positive areas correlated with HbA1c (r = 0.77, p < 0.0001 and r = 0.30, p = 0.034). 
Similarly, plasma AGEs and sRAGE levels were associated with HbA1c in the DM group (r = 0.32, p = 0.024 and r = 0.33, 
p = 0.014, respectively). In all DM patients, we found an association between the amount of valvular AGEs and the 
disease severity measured as aortic valve area (AVA; r = 0.68, p < 0.0001). Additionally, in DM patients with HbA1c > 7% 
(n = 24, 48%) we found that valvular expression of AGEs correlated with mean transvalvular pressure gradient  (PGmean; 
r = 0.45, p = 0.027). Plasma AGEs levels in the whole DM group correlated with AVA (r = − 0.32, p = 0.02),  PGmean 
(r = 0.31, p = 0.023), and  PGmax (r = 0.30, p = 0.03).
Conclusions: Our study suggests that poorly-controlled diabetes leads to increased AGEs and RAGE valvular accu-
mulation, which at least partially, might result in AS progression in DM patients.
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Background
Aortic stenosis (AS) is the most common cause of 
acquired valvular heart disease in the adult population, 
with 2–3% prevalence for individuals older than 65 years 
in developed countries [1]. AS is initiated as aortic valve 
sclerosis, associated with a mild valve thickening. Histo-
pathologic heterogeneity of AS indicates the involvement 
of cell dependent mechanisms that regulate calcium load 
in the valve leaflets, as well as the participation of differ-
ent cell types, including valvular interstitial cells (VICs), 
endothelial cells and cardiac leukocytes [2]. Under path-
ological conditions, such as inflammation or oxidative 
stress VICs can differentiate into myofibroblasts (causing 
fibrosis) and osteoblast-like cells (causing calcification) 
[2]. Diabetes mellitus (DM), a known cardiovascular risk 
factor, has also been reported as a risk factor for AS pro-
gression [3]. In patients with AS and concomitant type 2 
DM reduced systemic arterial compliance and left ven-
tricular dysfunction at the midwall level, corresponding 
to slightly depressed myocardial contractility have been 
shown [4]. Chronic hyperglycemia is a common feature 
of DM and has been related to vascular and inflammatory 
cell interactions with advanced glycation end products 
(AGEs) [5]. Advanced glycation is the irreversible attach-
ment of reducing sugars to the free amino groups of pro-
teins. Conditions such as DM rapidly accelerate AGE 
formation [6]. It has been shown that AGEs accumulation 
plays a key role in development of vascular calcification 
in DM patients [7–9]. AGEs, which are a heterogeneous 
group of molecules generated through non-enzymatic 
glycation and oxidation of proteins such as collagen, elas-
tin and laminin [10–12], lipids, and nucleic acids [10] can 
alter tissue function and its mechanical properties [10–
12]. Interestingly, it has been shown that chronic high 
dietary AGEs lead to increased arterial stiffness with sub-
sequent elevation of systolic blood pressure and inflam-
matory activation, which may lead to the development of 
vascular complications in type 2 DM [11]. AGEs modu-
late multiple cellular processes through the cross-linking 
of intracellular and extracellular matrix proteins [12] or 
binding to their cell surface receptor (RAGE), which pro-
duces excesses in inflammatory molecule production [13, 
14]. It has been shown that elevated circulating soluble 
RAGE (sRAGE) levels are associated with the presence of 
bicuspid aortic valve and associated aortopathies, inde-
pendently of aortic diameter [15]. Moreover, Hofmann 
et  al. [16] have shown in model using RAGE knock-out 
mice that both AGEs and RAGE are involved in the aortic 
leaflets calcification and subsequent AS. Low levels of 
both sRAGE and endogenous secretory receptor for 
RAGE (esRAGE), which are considered to be protective 
against AGEs, were shown as a very early marker of ini-
tial target organ damage in mild hypertensives [17] or a 
factor associated with negative coronary artery remod-
eling in diabetics [18]. Moreover, the concentration of 
sRAGE has been associated with increased arterial wall 
stiffening over time [19]. Despite numerous reports on 
AGE and RAGE involvement in the pathogenesis of car-
diovascular diseases little is known about mechanisms 
by which hyperglycemia-related increase of AGEs and 
RAGE affects inflammation and calcification within aor-
tic stenotic valves. We aimed to investigate whether in 
AS patients with concomitant DM, the severity of AS is 
associated with enhanced accumulation of both valvular 
and plasma AGEs and RAGE.
Methods
Study subjects
We enrolled 126 patients with isolated AS on tri-
cuspid aortic valve (nonDM group), including 50 AS 
patients with concomitant type 2 DM (DM group). 
Patients were hospitalized between August 2016 and 
February 2019 in the Department of Cardiovascu-
lar Surgery and Transplantology at the John Paul II 
Hospital, Krakow, Poland. Severe AS was defined by 
a mean transvalvular gradient  (PGmean) ≥ 40  mmHg 
and/or aortic valve area (AVA) < 1 cm2, based on tran-
sthoracic echocardiography, performed by an experi-
enced cardiologist on a Toshiba APLIO 80 (Toshiba, 
Tokyo, Japan) ultrasound machine. All patients were 
scheduled to undergo aortic valve replacement, fol-
lowing the Heart Team indication. Left ventricular 
ejection fraction (LVEF) was routinely measured dur-
ing echocardiography. The diagnosis of atherosclerosis 
was based on angiographically documented coronary 
artery stenosis > 20% diameter. Patients classified as 
having DM had to be diagnosed preoperatively based 
on fasting plasma glucose ≥ 7.0  mmol/L (126  mg/dL) 
on two separate occasions, HbA1c equal or exceeding 
6.5% (48  mmol/mol) or oral glucose tolerance test of 
140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) 
according to The International Expert Committee [20] 
and only individuals receiving insulin or oral hypo-
glycemic agents preoperatively were included in this 
study. Hypercholesterolemia was diagnosed based on 
medical records, cholesterol-lowering therapy or total 
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cholesterol of 5.0  mmol/L or more. Arterial hyperten-
sion was diagnosed based on a history of hypertension 
(blood pressure > 140/90 mmHg) or preadmission anti-
hypertensive treatment. Smoking was defined as the 
use of one or more cigarettes per day. The exclusion 
criteria were: angiographically documented coronary 
artery stenosis > 20% diameter, rheumatic AS, acute 
infection, diagnosed malignancy, endocarditis, chronic 
kidney disease, any previous heart surgeries, acute car-
diovascular event in the last 3  months before inclu-
sion, any concomitant valvular surgery and pregnancy. 
The valvular anatomy was confirmed intraoperatively 
by a cardiac surgeon, and bicuspid valve was used as 
an exclusion criterion. The Local Ethical Committee in 
Krakow approved the study and participants provided 
informed consent in accordance with the Declaration 
of Helsinki.
Laboratory analysis
At the day of valve replacement,  after an overnight fast 
venous blood  was drawn between 7:00 and 9:00 AM 
from the antecubital vein into citrated (9:1 of 0.106  M 
sodium citrate) or EDTA (both SARSTEDT, Nümbre-
cht, Germany) tubes. Blood was centrifuged at 2500g at 
20  °C for 20 min and stored in aliquots at − 80  °C until 
analysis. Blood drawn into serum tubes was centrifuged 
at 1600g at 4  °C for 10  min and stored at − 80  °C. To 
determine lipid profile, glucose and creatinine in serum, 
routine laboratory assays were used. Serum high-sensi-
tivity C-reactive protein (hsCRP) was determined using 
immunoturbidimetry (Roche Diagnostics, Mannheim, 
Germany). Fibrinogen was measured by the von Clauss 
method in citrated plasma (Instrumentation Laboratory, 
Bedford, MA, USA). Glycated hemoglobin HbA1c was 
determined using turbidimetric inhibition immunoassay 
TINIA in hemolysate prepared from whole blood (Roche 
Diagnostics, Mannheim, Germany). Serum fructosamine 
levels were measured using a colorimetric assay (Roche 
Diagnostics, Risch-Rotkreuz, Switzerland).
Enzyme‑linked immunosorbent assay (ELISA)
Human advanced glycation end products (AGEs; all 
species with the predominance of N(6)-Carboxym-
ethyllysine) and circulating soluble human receptor for 
advanced glycation end products (sRAGE) concentra-
tions in EDTA plasma samples were assayed quanti-
tatively using commercial ELISA kits (EIAab, Wuhan, 
China, no. E0263h and Boster Biological Technology, 
California, USA, no. EK0827, respectively) in accord-
ance with manufacturer’s instructions. Serum insulin 
levels were assessed using Insulin Human ELISA Kit 
(Invitrogen —Thermo Fisher Scientific, Waltham, MA, 
USA).
Aortic valves preparation
Valve samples embedded in Tissue Tec-OCT compound 
(Sakura, Torrance, CA, USA) were cryosectioned (4.5 μm 
thick sections) onto SuperFrost slides (Menzel-Glaser, 
Braunschweig, Germany) by a Leica CM 1520 cryostat. 
Transverse sections were taken from the mid and com-
missural areas of the leaflet and stored at − 20  °C until 
immunostaining.
Immunofluorescence analysis
Sections were fixed in ice-cold methanol-acetone (1:1) 
mixture. After endogenous peroxidase activity quench-
ing with 3%  H2O2 (15  min) at room temperature (RT) 
and blocking of unspecific background with 3% bovine 
albumin (BSA, Sigma Co, St. Louis, MO, USA) at RT in 
dark (30 min). Primary adequate antibodies against AGE 
(1:500; no. ab23722), tissue RAGE (1:100; no. ab3611), 
interleukin-6 (IL-6, 1:800; no. ab6672), and reactive oxy-
gen species (ROS) modulator 1 (ROMO1, indirectly eval-
uating ROS production; 1:100; no. ab121379) (all from 
Abcam, Cambridge, UK) were applied overnight at 4 °C. 
Primary antibodies were followed by the correspond-
ing secondary goat or mouse antibodies conjugated with 
fluorochrome AlexaFluor 488 or AlexaFluor 594 (Abcam, 
Cambridge, UK) (1:1000) at 4  °C for 1  h in dark. Dou-
ble-label immunofluorescence analyses were performed 
using the same antibodies. The co-localization of AGE 
and RAGE was performed. A negative control (without 
primary antibody incubation) was included routinely to 
all staining. Images were analyzed using Olympus BX 43 
microscope equipped with software (Cell Sense Stand-
ard, version 11.0.06). Per each valve 30 images were taken 
and the percentage of positively-stained areas was calcu-
lated as the extent of positive immunoreactive areas/total 
sample area as follows [21]:
The fluorescence intensity (FI) was computed as the 
ratio of fluorescence of positively and negatively stained 
areas. The investigators analyzing the data were blinded 
to the study groups. The ratio of valvular AGEs and 
sRAGE (AGEs/sRAGE) has also been calculated [22].
Statistical analysis
All statistical analysis were performed using STATIS-
TICA Version 12.5 (StatSoft STATISTICA™, Poland) 
program. Categorical variables were presented as num-
bers and percentages and were analyzed by Pearson’s χ2 
or two-tailed Fisher’s exact test. Continuous variables 
Σ of immunoreactive areas
Total section area
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were expressed as mean ± standard deviation (SD) or 
median and interquartile range [IQR]. Normality was 
analyzed by the Shapiro–Wilk test. The Student’s test 
was used for normally distributed continuous variables. 
Differences between groups were compared using the 
Mann–Whitney U test for non-normally distributed con-
tinuous variables. Associations between nonparametric 
variables were assessed by Spearman’s tests. The multi-
variate analyses were performed using linear regression 
models adjusted for potential confounders such as age, 
hypertension, hypercholesterolemia, and the use of sta-
tin and/or angiotensin-converting enzyme inhibitors. 
P-values of < 0.05 were considered as statistically sig-
nificant. The study was powered to have a 90% chance of 
detecting a 15% difference in valvular expression of dif-
ferent factors using a p-value of 0.01, based on the previ-
ous study [14]. In order to demonstrate such a difference 
or grater, the group size is equal to 44 patients, or more is 
required in each group.
Results
DM patients did not differ from the nonDM group 
with regard to demographic factors, but were more 
frequently obese (BMI > 30  kg/m2, Table  1). More DM 
Table 1 Characteristics of patients with aortic stenosis with or without concomitant diabetes mellitus (DM)
Data presented as numbers (percentages), mean ± SD or medians [interquartile range]. Categorical variables were analyzed by the Chi square test. The Mann–Whitney 
U or Student tests were used to compare differences between groups
AS aortic stenosis, DM type 2 diabetes mellitus, BMI body mass index, ACE inhibitors angiotensin converting enzyme inhibitors, LVEF left ventricular ejection fraction, 
AVA aortic valve area, hsCRP high-sensitivity C-reactive protein, HbA1c glycated hemoglobin, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high 
density lipoprotein cholesterol
Variable NonDM patients (n = 76) DM patients (n = 50) p‑value
Age, years 68 [66–72] 70 [66–74] 0.18
Male, n (%) 41 (53.9) 31 (62) 0.37
BMI, kg/m2 28.4 [26.6–31.2] 31.3 [28.7–34.5] < 0.001
Risk factors, n (%)
 Arterial hypertension 70 (92.1) 50 (100) 0.08
 Hypercholesterolemia 20 (26.3) 10 (20) 0.52
 Current smoking 9 (11.8) 8 (16) 0.60
Medications, n (%)
 Beta-blockers 61 (80.3) 47 (94) 0.038
 Acetylsalicylic acid 52 (68.4) 40 (80) 0.22
 ACE inhibitors 53 (69.7) 45 (90) 0.008
 Statins 56 (73.7) 46 (92) 0.011
 Insulin 0 14 (28) < 0.0001
 Metformin 0 36 (72) < 0.0001
Echocardiographic parameters
 Mean gradient, mmHg 48 [42–59] 52 [43–66] 0.067
 Maximum gradient, mmHg 82.3 ± 14.2 89.2 ± 12.3 0.054
 LVEF, % 60 [55–65] 60 [58–64] 0.39
 AVA,  cm2 0.86 [0.7–0.95] 0.78 [0.6–0.8] 0.048
Laboratory investigation
 Fibrinogen, g/L 3.4 ± 0.8 3.6 ± 0.6 0.28
 Creatinine, µmol/L 74 [65–89] 81 [74–100] 0.011
 hsCRP, mg/L 1.2 [1.0–4.0] 1.0 [1.0–2.0] 0.34
 Glucose, mmol/L 5.2 [4.9–5.6] 7.5 [5.9–9.1] < 0.0001
 HbA1c, % 5.4 [5.2–5.7] 6.8 [6.3–7.8] < 0.0001
 Insulin, µIU/mL 16.5 [13.1–19.9] 16.4 [12.3–23.4] 0.41
 Fructosamine, µmol/L 225 [217–236] 262 [241–291] < 0.0001
 TC, mmol/L 4.1 [3.7–4.8] 3.8 [3.0–4.6] 0.06
 LDL-C, mmol/L 2.6 [2.1–3.3] 2.3 [1.5–3.1] 0.17
 HDL-C, mmol/L 1.3 [1.1–1.6] 1.2 [1.0–1.4] 0.039
 Triglycerides, mmol/L 1.2 [0.9–1.8] 1.5 [1.2–2.0] 0.27
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patients used statins, beta-blockers and angiotensin 
converting enzyme (ACE) inhibitors compared to sub-
jects from the nonDM group (all p < 0.05; Table 1). The 
median time of DM duration was 11 [7–18] years, and 
DM patients had 44.2% higher glucose, 25.9% higher 
HbA1c, and 16.4% higher fructosamine levels com-
pared to nonDM subjects (all p < 0.05; Table  1). DM 
patients were also characterized by slightly poorer 
renal function (Table  1). No intergroup differences 
were found in other laboratory parameters (Table  1). 
Among DM patients, as many as 24 (48%) individuals 
had poorly controlled diabetes, defined as HbA1c > 7% 
(Table 2).
Valvular expression of AGEs and RAGE
The thickness of the aortic valve leaflets was 
greater in DM patients compared to nonDM valves 
(1926.32 ± 197.85 µm vs. 1298.32 ± 183.37 µm, p = 0.017) 
(Fig. 1a, b).
Valvular expression of AGEs and RAGE was mostly 
detected at the aortic site of the leaflets and presented 
a diffused pattern of fluorescence for AGEs, whereas 
RAGE expression was more condensed and located 
mainly on the edge of the leaflets (Fig.  1c–f). Valvu-
lar AGE expression was 6.6-fold higher in DM com-
pared to nonDM patients (15.53 [9.96–23.28]% vs. 2.05 
[1.21–2.85]%, p < 0.001) (Fig. 1c, d). Similarly, in the DM 
group we found 1.8-fold higher expression of valvular 
Table 2 Comparison of  AS  patients with  concomitant type 2 DM stratified according to  glycated hemoglobin levels 
(HbA1c)
Data presented as numbers (percentages), mean ± SD or medians [interquartile range]. Categorical variables were analyzed by the Chi square test. The Mann–Whitney 
U or Student tests were used to compare differences between groups
AGEs advanced glycation end products, RAGE receptor for AGEs, for abbreviations see Table 1
Variable Patients with DM and HbA1c > 7% 
(n = 24)
DM and HbA1c ≤ 7% (n = 26) p‑value
Age, years 74 [70–76] 70 [66–73] 0.12
Male, n (%) 13 (54.2) 18 (69.3) 0.38
BMI, kg/m2 30.4 [26.6–31.2] 32.2 [28.7–34.5] 0.30
Risk factors, n (%)
 Arterial hypertension 24 (100) 26 (100) 0.99
 Hypercholesterolaemia 7 (29.2) 3 (11.5) 0.16
 Current smoking 2 (8.3) 6 (23.1) 0.25
Medications, n (%)
 Beta-blockers 21 (87.5) 26 (100) 0.10
 Acetylsalicylic acid 19 (79.2) 21 (80.8) 0.99
 ACE inhibitors 22 (91.7) 23 (88.5) 0.99
 Statins 21 (87.5) 25 (96.2) 0.34
 Insulin 14 (58.3) 0 < 0.0001
 Metformin 10 (41.7) 26 (100) < 0.0001
Echocardiographic parameters
 Mean gradient, mmHg 61 [46–67] 44 [41–50] 0.003
 Maximum gradient, mmHg 95 [72–109] 64 [58–77] <0.00001
 LVEF, % 60 [55–65] 60 [58–64] 0.98
 AVA,  cm2 0.65 [0.56–0.80] 0.85 [0.8–0.9] < 0.0001
Laboratory investigation
 Creatinine, µmol/L 91 [88–101] 79 [73–99] 0.19
 hsCRP, mg/L 1.0 [1.0–2.0] 1.0 [1.0–2.0] 0.53
 Glucose, mmol/L 6.8 [6.2–8.4] 6.4 [5.5–7.5] 0.21
 Insulin, µIU/mL 16.2 [12.4–23.3] 16.3 [12.4–23.4] 0.89
 Fructosamine, µmol/L 271 [250–304] 259 [231–266] 0.04
 Valvular AGEs, % 23.3 [17.5–28.1] 10.8 [9.3–13.5] < 0.00001
 Valvular RAGE, % 8.1 [6.6–8.5] 5.7 [4.8–7.7] 0.015
 Plasma AGEs, ng/mL 9.3 [8.5–12.0] 9.6 [8.6–10.4] 0.55
 Plasma sRAGE, pg/mL 1977 [1596–2455] 1988 [1517–2613] 0.70
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RAGE than in the nonDM group (6.8 [4.9–8.45]% vs. 
2.4 [1.56–3.02]%, p < 0.001) (Fig.  1e, f ). Of note, AGEs 
and RAGE showed co-expression in 51.5% of positively 
stained areas (Fig.  1i). DM compared to nonDM valves 
were characterized by higher ROS-positive area (2.28 
[1.6–3.09]% vs 1.15 [0.94–1.4]%; p < 0.0001; Fig.  1g, h). 
The valvular expression of IL-6 tended to be increased 
in DM compared to nonDM patients (1.57 [0.96–2.15]% 
vs. 1.18 [0.96–1.8]%; p = 0.062). There were no associa-
tions between valvular ROS or IL-6 expression and echo 
parameters in both patient groups.
In DM patients the amount of valvular AGEs was posi-
tively associated with HbA1c and fructosamine levels 
(Fig. 2a, b). The valvular RAGE correlated positively with 
HbA1c (Fig. 2c) but not with plasma glucose, insulin or 
fructosamine levels (data not shown). In DM, but not in 
nonDM patients, we found negative association between 
the amount of valvular AGEs and aortic valve area (AVA; 
Fig. 2d), even after adjustment for potential confounders 
(Table  3). Similar association was not observed for val-
vular RAGE (Table 3). Furthermore, in DM patients with 
HbA1c > 7% (n = 24, 48%), we observed 1.2-fold higher 
expression of AGEs compared to those with HbA1c ≤ 7% 
(Table 2; Fig. 2e) which correlated with  PGmean (Fig. 2f ).
Plasma levels of AGEs and sRAGE
DM compared to nonDM patients had 12-fold higher 
plasma concentrations of AGEs (9.55 [8.56–10.92] 
vs. 0.73 [0.68–0.77] ng/mL; p < 0.0001) and 1.3-fold 
higher plasma sRAGE levels (1982 [1517–2613] vs. 
858 [648–971] pg/mL; p < 0.0001). Of note, in the 
DM group plasma AGEs correlated with sRAGE lev-
els (r = 0.61, p < 0.0001) and plasma concentrations 
of AGEs and sRAGE were positively associated with 
HbA1c levels (Fig.  3a, b). Importantly, in the DM 
group, plasma AGEs levels positively correlated with 
fructosamine (Fig.  3c). In DM, but not in nonDM 
patients, HbA1c was associated with fructosamine lev-
els (r = 0.54, p < 0.0001). Associations of plasma AGEs 
and sRAGE levels with HbA1c or fructosamine were 
not observed in the nonDM group (data not shown).
Moreover, in the DM group, plasma levels of AGEs 
correlated positively with valvular AGEs expression 
(r = 0.67, p = 0.037) but valvular RAGE was not associ-
ated with sRAGE (p > 0.05).
There were no associations between echo parameters 
and HbA1c or glucose levels in the whole group of DM 
subjects. However, DM patients with HbA1c > 7.0% 
compared to those with HbA1c ≤ 7.0% were character-
ized by higher  PGmax and  PGmean (Table 2; Fig. 4a).
In DM patients plasma levels of AGEs and sRAGE 
were associated with the disease severity reflected 
by AVA (Fig.  4b, c), even after adjustment for defined 
confounders (Table  3). Moreover, plasma AGEs (but 
not sRAGE) levels correlated positively with  PGmean 
(Fig.  4d), while  PGmax was associated with both AGE 
and sRAGE plasma levels (Fig. 4e, f ). However, associa-
tions of transvalvular gradients with plasma AGEs and 
sRAGE were no more significant after adjustment for 
defined confounders (Table 3).
Fig. 1 Expression of AGEs and RAGE within aortic stenotic valves. Representative microphotographs of aortic stenotic valves dissected from 
patients with aortic stenosis (nonDM) or aortic stenosis with concomitant type 2 diabetes mellitus (DM). a, b The thickness of the leaflets stained 
with hematoxylin, c, d the valvular expression of advanced glycation end products (AGEs) and e, f their receptor (RAGE), g, h the expression of 
reactive oxygen species (ROS) modulator 1 (indirect staining for ROS), and i co-localization of AGEs (green) and RAGE (red). Cell nuclei are stained in 
blue (DAPI). *Aortic site of the leaflet. Original magnification ×40
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Fig. 2 Associations of valvular AGEs and RAGE with glycation markers and echocardiographic parameters in patients with AS and concomitant 
DM. Associations of: a the expression of valvular advanced glycation end products (AGEs) with glycated hemoglobin (HbA1c), b valvular AGEs 
with serum fructosamine, c valvular AGEs receptor (RAGE) with HbA1c, d valvular AGEs with aortic valve area (AVA), e expression of valvular AGEs 
stratified according to elevated HbA1c levels, and f valvular AGEs with mean transvalvular pressure gradient (PG)
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Ratio of valvular AGEs and plasma sRAGE levels (AGEs/
sRAGE)
We found significant associations between the AGEs/
sRAGE ratio and glucose levels (r = 0.36, p = 0.077), 
HbA1c (r = 0.46, p = 0.0004) as well as with echocardio-
graphic parameters such as AVA (r = − 0.41, p = 0.0033), 
 PGmean (r = 0.32, p = 0.019),  PGmax (r = 0.37, p = 0.007). 
However, after adjustment for defined confounders 
all estimates showed only a tendency to be significant 
(Table 3).
Discussion
To the best of our knowledge, this study is the first to 
show that: (1) patients with AS and concomitant DM 
compared to nonDM patients with tricuspid aortic 
valves, demonstrate abundant valvular accumulation 
of AGEs and RAGE associated with AS severity. Inter-
estingly, poorly controlled DM was associated with the 
highest valvular AGEs expression; (2) the expression of 
valvular AGEs corresponded to AGEs level in plasma 
but this association held no true for valvular RAGE and 
sRAGE, and (3) plasma levels of AGEs and sRAGE were 
correlated with AVA but not with transvalvular pressure 
gradients.
AGEs involvement in AS
Our results showing that enhanced valvular expression 
of AGEs associated with AS severity in AS patients with 
concomitant DM are in line with studies performed in 
mice, in which AGEs accumulation resulted in aortic 
valve degeneration [16]. Previously, we have shown that 
diabetes is associated with increased valvular inflam-
mation, measured by valvular CRP expression [23]. The 
present study provides the initial evidence for a pro-
inflammatory effect of valvular AGEs accumulation. 
Despite the fact that AGEs are accumulated as a result 
of hyperglycemia, their effects can occur independently 
of glycemic control and their levels better predicted 
both DM progression and vascular calcification than 
HbA1c [24]. Although glycemic control is important, 
it is not sufficient to prevent complications of diabetes. 
Other factors, such as oxidative stress, may be more 
important mediators of advanced glycation than hyper-
glycemia per se in patients already receiving interven-
tions directed to improve glycemic control [6]. On the 
other hand, our study provided additional data that 
both biomarkers of long-term glycemic control (HbA1c 
and fructosamine) show associations with plasma and 
valvular AGEs. Arguably, they may give insight into dis-
ease course in AS patients with concomitant DM, espe-
cially in those with mild-to-moderate AS. However, 
further studies are needed to explore this issue.
It is known that AGEs accumulation in the extracel-
lular matrix of vessels leads to structural and functional 
changes of collagen and subsequent cardiovascular 
complications [22]. Therefore, it might be hypothesized 
that more severe AS observed in patients with con-
comitant DM is a result of AGE-related valvular col-
lagen cross-linking leading to enhanced inflammation, 
oxidative stress, and calcification of the leaflets. Study-
ing a cohort with confirmed normal-flow high-gradient 
AS, we observed an association between valvular AGEs 
expression and AVA in DM. This observation was fur-
ther corroborated by correlation of valvular AGEs 
expression and mean transvalvular pressure gradient. 
Considered the fact that also plasma AGEs levels were 
associated with AVA, it becomes evident that AGEs 
have multilevel interrelation with AS severity in diabet-
ics, even at the very late stage of the disease, where sur-
gical intervention is inevitable.
Our novel observation is that poorly controlled DM 
was associated with the highest valvular AGEs expres-
sion, which correlated not only with AVA but also 
with transvalvular pressure gradients. The influence of 
diabetes on AS progression has been previously stud-
ied. Katz et al. [7] have shown that the metabolic syn-
drome and DM are associated with increased risk of 
valvular calcification, and AS prevalence is associated 
with increasing number of metabolic syndrome com-
ponents. Kamalesh et al. [25] have shown an influence 
of diabetes on AS progression in patients with mild AS, 
Table 3 Multivariate associations between echocardiographic parameters and valvular or plasma AGEs and RAGE levels
All models were adjusted for age, hypertension, hypercholesterolemia, the use of statin, and angiotensin-converting enzyme inhibitors. CI confidence interval; for 
other abbreviations see Tables 1 and 2
Variable AVA, estimate (95% CI) p‑value Mean gradient, 
estimate (95% CI)
p‑value Maximum gradient, 
estimate (95% CI)
p‑value
 Valvular AGEs, % − 0.29 (− 0.10; − 0.47) 0.0035 0.24 (0.05; 0.43) 0.014 0.34 (0.15; 0.52) 0.0005
 Valvular RAGE, % − 0.13 (− 0.32; 0.066) 0.19 0.082 (− 0.11; 0.28) 0.41 0.09 (− 0.11; 0.29) 0.36
 Plasma AGEs, ng/mL − 0.20 (− 0.0041; − 0.39) 0.045 0.13 (− 0.069; 0.32) 0.20 0.04 (− 0.15; 0.24) 0.66
 Plasma sRAGE, pg/mL − 0.26 (− 0.063; − 0.45) 0.01 0.13 (− 0.07; 0.33) 0.20 0.18 (− 0.16; 0.38) 0.071
 Valvular AGEs/sRAGE ratio − 0.19 (0.007; − 0.39) 0.058 0.18 (− 0.02; 0.38) 0.078 0.19 (− 0.008; 0.39) 0.059
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but not in those with heavily calcified stenotic valves. 
They speculated that once the valve is calcified, the dia-
betes-driven inflammation may play less of a role in AS 
progression than in a valve with mild lesions. Recently, 
Larsson et  al. in a prospective cohort study compris-
ing > 70,000 individuals have confirmed that type 2 
DM is associated with an increased risk of AS (hazard 
ratio: 1.34; 95% confidence interval 1.05–1.71) [26]. On 
the contrary, Testuz et al. [27] failed to demonstrate an 
association between AS progression and metabolic syn-
drome or diabetes during 3-years follow-up. However, 
the authors evaluated only levels of fasting glucose, 
reflecting short-term glucose dynamics. Neither the 
levels of HbA1c, fructosamine nor AGEs in their cohort 
were assessed [27], while our study showed that in AS 
patients with well-controlled type 2 DM an influence of 
hyperglycemia on AS severity is minor.
RAGE involvement in AS
Despite the role of RAGE in vascular calcification has 
been previously demonstrated in animal models [28, 
29], our study showed that RAGE in contrast to AGEs is 
poorly associated with AS severity measures. Moreover, 
we found no associations between AGE/sRAGE ratio and 
AS severity after adjustment for potential confounders, 
while this ratio has been suggested as a more sensitive 
marker than single factors [22, 30]. These discrepancies 
may be connected with the fact that there are differ-
ent species of RAGE, including the membrane RAGE, 
responsible for the harmful effects of AGEs and circulat-
ing RAGE isoforms which are protective against AGEs 
due to competing with the tissue RAGE for binding of 
AGEs [31]. Thus, this dual nature of RAGE, together 
with an increased consumption of AGE by sRAGE in 
subjects with impaired glucose metabolism [32] may 
disturb a direct associations between RAGE and param-
eters describing AS severity. Moreover, we showed rela-
tively high levels of sRAGE observed in DM compared 
to nonDM patients, while there are studies reporting 
decreased, increased or unchanged sRAGE levels in DM 
patients compared to subjects without DM [33–35]. This 
difference may be explained by a presence of several con-
founding factors, with major impact of DM duration. 
It has been shown that the longer duration of DM the 
higher AGEs generation and AGE-stimulated increased 
RAGE expression [36]. Moreover, the presence of hyper-
tension, use of antihypertensive drugs or inflammatory 
diseases can affect plasma sRAGE levels [36].
Study limitations
This study has several limitations. The number of study 
participants was limited, however, the study was ade-
quately powered to detect intergroup differences in AGEs 
levels. Moreover, almost half of the DM patients had 
well-controlled diabetes with HbA1c < 7%. This could be 
a reason that we failed to show associations of valvular 
Fig. 3 Associations of plasma AGEs and RAGE with glycation markers 
in patients with AS and concomitant DM. Associations of: a plasma 
levels of advanced glycation end products (AGEs) with glycated 
hemoglobin (HbA1c), b plasma levels of AGE receptor (RAGE) with 
HbA1c, c plasma AGEs with serum fructosamine levels
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Fig. 4 Associations of plasma AGEs and RAGE with echocardiographic parameters in patients with AS and concomitant DM. Associations of: a 
mean and maximal transvalvular pressure gradients (PG) stratified according to elevated levels of glycated hemoglobin (HbA1c), b plasma levels 
of advanced glycation end products (AGEs) with aortic valve area (AVA), c plasma levels of AGEs receptor (RAGE) with AVA, d plasma levels of AGEs 
with mean PG or e maximal PG, and f plasma RAGE levels with maximal PG
Page 11 of 12Kopytek et al. Cardiovasc Diabetol           (2020) 19:92  
AGEs and RAGE accumulation with valvular inflam-
mation or oxidation. On the other hand, more sensitive 
markers of inflammation and oxidation, or using another 
type of antibodies for immunostaining, could be more 
informative. Second, although the analysis of valvular 
expression of AGEs and RAGE along with IL-6 and ROS 
was semiquantitative, but assessed by two independent 
investigators, results of such analyses should be inter-
preted with caution. Third, metformin has the ability to 
reduce AGEs accumulation [37], and it should be men-
tioned that most of DM patients in our cohort received 
this drug. AGEs levels in newly diagnosed or untreated 
DM patients might be higher.
Conclusions
We conclude that AGEs and RAGE accumulate within 
stenotic aortic valves in DM patients, and the degree of 
this accumulation is associated with AS severity. Moreo-
ver, we found that plasma AGE and sRAGE levels were 
associated with AVA, thus they may be considered as 
new biomarkers of the AS course in patients with con-
comitant type 2 DM. Further studies are urgently needed 
to elucidate whether more strict control of diabetes is 
capable of slowing AS progression in patients with mild-
to-moderate valvular disease.
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